ActoGeniX was founded in June 2006 as a spin-off of the Flemish Institute for Biotechnology (VIB) and the University of Ghent. ActoGeniX develops therapies, based on its patented TopAct™ technology platform, which address major diseases requiring intensive medical care, including gastrointestinal problems, auto-immunity diseases, allergies and metabolic disorders. TopAct™ uses micro-organisms for the oral administration of proteins. ActoGeniX’s first product – for treating Crohn’s disease - has already been successfully tested on patients.
- Activity: Oral delivery of biopharmaceuticals
- Website: www.actogenix.com
- Location: Belgium
- Entry: 2006
- Platform: Health & Care